SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium's inaugural Interlab Study. This milestone collaboration underscores the exceptional precision and accuracy of Mission Bio's Tapestri platform and supports Tapestri’s potential to become a standard approach used by the genome editing community, particularly to ensure safer, more effective gene-edited therapies.
The NIST Genome Editing Consortium (GEC) was created to meet the growing demand for enhancing the confidence in genome editing technologies by supporting quality and standardization in analysis. In 2018, Mission Bio joined the consortium to provide single-cell resolution of genome editing outcomes. The GEC’s first Interlab Study aimed to evaluate various DNA detection technologies used to confirm sequence variants within known mixed cell populations. NIST provided qualified whole genome samples to 14 collaborators to conduct in-depth assessments of technologies reporting variant size and frequency.
Initial data from the Interlab Study presented earlier this year by NIST Genome Editing Program Leader Samantha Maragh, PhD, showed that Mission Bio's Tapestri platform performed as follows when provided highly characterized samples from NIST:
- Strong Agreement: The observed variant frequencies closely aligned with NIST's qualified values based on droplet digital polymerase chain reaction (ddPCR),
- Robust Sensitivity: Tapestri confirmed the presence and sequence of variants (indels) ranging from 1bp, up to 100kb at frequencies as low as 0.1%,
- Single-Cell Detection: Tapestri contributes a unique dimension to the study by enabling targeted per-cell and zygosity measurements. This per-cell resolution variant allele frequency analysis enables the unique ability to reveal the true heterogeneity of cell populations in a targeted manner.
Mission Bio recently announced the commercial availability of the tool used in the Interlab Study, the Tapestri Genome Editing Solution, to the public in September.
“As demonstrated by the initial results from the NIST Genome Editing Consortium Interlab Study, our technology uniquely brings targeted single-cell detection to the NIST initiative, delivering per cell resolution measurements,” said Todd Druley, MD, PhD, Chief Medical Officer of Mission Bio. “We look forward to continuing work with NIST and the consortium members and providing a single-cell multi-omics platform to hopefully improve quality control and wider adoption of genome editing technologies.”
Samantha Maragh, Genome Editing Program Leader at NIST will deliver an update to the Interlab Study in a poster presentation, “NIST Genome Editing Consortium interlab study to evaluate the performance of DNA detection technologies in use for confirming genome editing,” at the upcoming European Society of Gene and Cell Therapy (ESGCT) conference in Brussels Belgium, Oct 24 - 27.
“Our mission within the NIST Genome Editing Program is to shed light on challenges and enhance the confidence in utilizing genome editing technologies across the vast landscape of life sciences and clinical practice,” said Dr. Maragh. “The initial Interlab Study findings underscore the value of bringing together experts and the importance of standardization in the field. We look forward to our continued collaboration with innovative technology makers within the consortium.”
On November 2, Mission Bio will be participating in the “NIST Genome Editing Consortium Public Workshop,” being held in Rockville, Maryland. The one-day public workshop hosted by NIST will discuss current and future efforts of the NIST Genome Editing Consortium.
About Mission Bio
Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multi-omic analysis. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.
